Sign In
Buy MNOV
$1.36
+0.0600 (+4.62%)
At Close: Jun 23, 2026
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
07:00pm, Tuesday, 26'th May 2026
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened
03:43am, Wednesday, 08'th Apr 2026
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.43 and traded as high as $1.43. Medic
MediciNova to Participate at the 38th Annual ROTH Conference
07:00am, Monday, 16'th Mar 2026
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
03:18am, Thursday, 26'th Feb 2026
Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat reports. One eq
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
06:00pm, Thursday, 29'th Jan 2026
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts
02:04am, Saturday, 10'th Jan 2026
Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat repo
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
02:00am, Wednesday, 07'th Jan 2026
MediciNova (NASDAQ: MNOV - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies b
2026 New Year's Greetings from the CEO
09:00am, Tuesday, 06'th Jan 2026
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange�
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
06:00am, Tuesday, 18'th Nov 2025
LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
06:00pm, Thursday, 06'th Nov 2025
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
07:00pm, Thursday, 30'th Oct 2025
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients Study published in the J
